Flosonics Medical Closes $20M Series C Financing for Wearable Doppler Ultrasound for Hemodynamic Assessments

Flosonics Medical has closed US$20 million Series C financing led by New Leaf Venture Partners, with participation from existing investors Arboretum Ventures, Genesys Capital, and iGan Partners, to advance innovation and drive market adoption of FloPatch, a first-in-class wearable Doppler ultrasound device for hemodynamic assessments.

Flosonics Medical plans to use the Series C investment to accelerate commercial growth, expand indications for use, and continue evidence generation. The company aims to address the growing demand for wearable AI-assisted sensors to improve patient management inside and outside the hospital.

Our investment in Flosonics is driven by the clear and significant impact their technology will have on patients in critical situations, and the quality of the team behind it. Flosonics Medical stands at the forefront of wearable ultrasound, and we look forward to contributing to their continued success,” said Vijay Lathi, Co-Founder and Managing Director at New Leaf Venture Partners, who will join Flosonics Medical’s board of directors.

This investment not only validates our success to date, but also enables us to accelerate our plans for expansion and innovation. We are committed to using this funding to further improve the standard of care for critically ill patients with FloPatch and to expand our reach into new markets,” said Joe Eibl, CEO of Flosonics Medical, the Canada-based medical device company founded in 2015 to research and develop innovative ultrasound technology.

en_GBEnglish (UK)